Vera Therapeutics Reports Positive Final ORIGIN 3 Efficacy Analysis

The company said the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy was presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine.